Ohsu

With OHSU contingency planning for up to $200 million in research funding that could be vulnerable to cuts, the incoming president pledged to be transparent about the difficult choices that could be coming down the pike.

Dr. Robert Macauley of OHSU is one of the few pediatricians in the U.S. who is certified in palliative medicine. His memoir is called, "Because I Knew You: How Some Remarkable Sick Kids Healed A Doctor's Soul."

Citing concerns that the deal could increase out-of-pocket health care costs and reduce choices, five Oregonians charged with representing the public’s interest have recommended state regulators reject a deal between OHSU and Legacy Health.

Last week, the Trump administration canceled key panels organized by the National Institutes of Health. The cancellations raise concerns among local researchers and healthcare professionals in Oregon about potential cuts to vital research funding. Currently, over $500 million in NIH-funded projects are ongoing in Oregon, supporting more than 5,000 jobs.

In a wide-ranging interview with OPB, Druker discussed the work he hopes to do in the future, and the message he wants to send to Oregon Health & Science University.

Dr. Brian Druker may be best known for his pioneering work on the cancer drug Gleevec, which dramatically increased the survival rate for a type of leukemia.

Stadum previously served as general counsel to OHSU and chief operating officer for the Knight Cancer Institute.

Oregon Governor Tina Kotek said she wants a more transparent process for selecting the next OHSU president.

OHSU’s board of directors intends to quickly replace President Danny Jacobs, who is resigning. Oregon Gov. Tina Kotek's office wants the board to take more time.

OHSU relies heavily on a single supplier, Baxter International, which suffered major damage to a critical North Carolina factory in Hurricane Helene.